- Maxime
Ranger, PhD, MBA
- Chief Executive Officer,
- Chairman of the board
Via rectal administration, this treatment aims to promote the regeneration of the enteric nervous system which is otherwise missing from the colon of patients, most of them being young children. The therapy is designed to also globally improve intestinal functions in these children, thereby offering significant hope for their well-being.
News
May 8th 2024
Neurenati Therapeutics Strengthens Its Board of Directors With the Appointment of Dr. Marielle Cohard-RadiceApril 18th 2024
Neurenati Therapeutics Concludes a Second Seed Financing of 1.7 Million $ With the Support of Impulsion PMEFebruary 29th 2024
Neurenati Therapeutics Concludes a 1.2 Million $ Seed Financing Round to Develop NEU-001 as a Promising Therapy for Hirschsprung DiseaseFebruary 29th 2024
Innovative treatment for rare Hirschsprung's diseaseA pioneering biotechnology company
Based in Montreal, Neurenati Therapeutics is a pioneering biotechnology company developing an innovative treatment for Hirschsprung disease. Nicolas Pilon, an expert in rare diseases, and Rodolphe Soret, a specialist in neuro-gastroenterology, have combined their expertise to develop an innovative treatment for Hirschsprung disease. With the additional support from the serial entrepreneur Maxime Ranger and various experts in medicine, gastroenterology, and rare disease clinical trials, the company is committed to bringing this treatment into clinical practice.
- Nicolas
Pilon, PhD
- Chief Scientific Officer,
- Cofounder Neurenati
- Rodolphe
Soret, PhD
- Director of the board,
- Cofounder Neurenati
- Alexandre P.
Lebeaut, MD
- Drug Development Advisor,
- Director of the board
- Marielle
Cohard-Radice, MD
- Clinical Development Consultant,
- Director of the board
- Benoit
Doré, PhD
- Portfolio Manager Axelys,
- Director of the board
- Marie-Eve
Bordeleau, PhD
- Senior Director,
- Pre-Clinical Development
- Patrick
Colin, BPharm, PhD
- Clinical Development,
- Consultant
- Dana
Matzen, PhD
- Senior Business Advisor to the CEO
- Francois
Boutin , CPA
- Acting Chief Financial Officer,
- Comptinc
Our technology
Challenge:
Hirschsprung disease represents a potentially fatal congenital malformation characterized by the absence of the enteric nervous system in the colon. This condition leads to contraction of the segment lacking the enteric nervous system, causing obstruction due to fecal matter (megacolon). The enteric nervous system plays a crucial role in other gastrointestinal functions, explaining the increased risk of systemic infections from intestinal microbes in children with Hirschsprung disease.
Currently, the standard treatment involves surgical removal of the affected segment, followed by reconnection of the innervated colon to the anus. Unfortunately, post-surgical complications such as fecal incontinence and enterocolitis often result in hospital readmissions and additional surgeries.
© Mayo Foundation for Medical Education & Research
© Trends in Molecular Medecine
Treatment:
Our innovative approach is based on regenerative medicine, offering a non-surgical alternative. We have demonstrated that the Glial cell-Derived Neurotrophic Factor (GDNF) administered via rectal enema stimulates the formation of a new enteric nervous system in the colon of three Hirschsprung disease mouse models. This newly created enteric nervous system significantly improves gastrointestinal functions, prolonging the life of a significant proportion of these mice. Recent data demonstrate that GDNF, in addition to its beneficial effects on the formation of the enteric nervous system, also exerts a positive influence on the overall intestinal ecosystem.
Indeed, it appears to promote improvement in several essential components, such as strengthening the intestine-specific immune system, maintaining the integrity of the intestinal epithelial barrier, and positively modulating the intestinal microbiota. These findings offer promising insights into the overall and multifunctional impact of GDNF on intestinal health, thus providing new avenues for the treatment of Hirschsprung disease and potentially other intestinal pathologies.